Anticoagulation with bivalirudin is associated with improved biocompatibility in patients supported on microaxial flow pumps
{{output}}
Objective: To evaluate whether an institutional shift from anticoagulation with heparin to bivalirudin in Impella 5.5 patients altered bleeding or thrombotic rates, transfusion dependency, or device biocompatibility. ... ...
